RARE vs RYAN · rev $560.2M vs P/E 43, rev $2.46B
Ultragenyx (RARE) versus Ryan Specialty Group Holdings Inc (RYAN) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Ryan Specialty Group Holdings Inc (RYAN) is a insurance - specialty company listed on NYSE.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
Latest reported RYAN revenue for 2024-12-31 was $2.46B. Net income was $229.9M. Revenue was up 21.2% from 2023-12-31 to 2024-12-31. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
RARE currently screens at market cap $2.79B. RYAN currently screens at market cap $9.33B and trailing P/E 43.1.
Not investment advice. Open the RARE and RYAN stock pages for the full models.
Not investment advice.